Market Cap
₹237.4b
Last Updated
2020/10/27 12:59 UTC
Data Sources
Company Financials
Executive Summary
Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. More Details
Rewards
Risk Analysis
No risks detected for 500680 from our risk checks.
Snowflake Analysis
Flawless balance sheet with proven track record.
Similar Companies
Share Price & News
How has Pfizer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 500680 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
2.8%
500680
-1.7%
IN Pharmaceuticals
-0.6%
IN Market
1 Year Return
30.7%
500680
45.4%
IN Pharmaceuticals
0.9%
IN Market
Return vs Industry: 500680 underperformed the Indian Pharmaceuticals industry which returned 45.4% over the past year.
Return vs Market: 500680 exceeded the Indian Market which returned 0.9% over the past year.
Shareholder returns
| 500680 | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.8% | -1.7% | -0.6% |
| 30 Day | 4.5% | -0.8% | 4.0% |
| 90 Day | 19.5% | 11.7% | 5.7% |
| 1 Year | 40.0%30.7% | 47.2%45.4% | 2.6%0.9% |
| 3 Year | 221.8%196.6% | 22.6%19.3% | -2.8%-7.4% |
| 5 Year | 121.4%100.1% | -0.2%-3.7% | 39.9%29.5% |
Price Volatility Vs. Market
How volatile is Pfizer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall St
How Pfizer Limited (BOM:500680) Delivered A Better ROE Than Its IndustryValuation
Is Pfizer undervalued compared to its fair value and its price relative to the market?
45.14x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 500680 (₹5137.8) is trading above our estimate of fair value (₹968.52)
Significantly Below Fair Value: 500680 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 500680 is poor value based on its PE Ratio (45.1x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: 500680 is poor value based on its PE Ratio (45.1x) compared to the Indian market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 500680's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 500680 is overvalued based on its PB Ratio (6.9x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
27.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pfizer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Check out Pfizer's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
- Pfizer competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Pfizer performed over the past 5 years?
22.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 500680 has high quality earnings.
Growing Profit Margin: 500680's current net profit margins (24.5%) are higher than last year (21.3%).
Past Earnings Growth Analysis
Earnings Trend: 500680's earnings have grown significantly by 22.4% per year over the past 5 years.
Accelerating Growth: 500680's earnings growth over the past year (15.6%) is below its 5-year average (22.4% per year).
Earnings vs Industry: 500680 earnings growth over the past year (15.6%) exceeded the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: 500680's Return on Equity (15.3%) is considered low.
Next Steps
Financial Health
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: 500680's short term assets (₹30.5B) exceed its short term liabilities (₹8.7B).
Long Term Liabilities: 500680's short term assets (₹30.5B) exceed its long term liabilities (₹1.4B).
Debt to Equity History and Analysis
Debt Level: 500680 is debt free.
Reducing Debt: 500680 has no debt compared to 5 years ago when its debt to equity ratio was 0.1%.
Debt Coverage: 500680 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 500680 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Pfizer current dividend yield, its reliability and sustainability?
0.19%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 500680's dividend (0.19%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.56%).
High Dividend: 500680's dividend (0.19%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: 500680 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.
Growing Dividend: 500680 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: 500680 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 500680's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.7yrs
Average management tenure
CEO
Sridhar Subramaniam (52 yo)
4.58yrs
Tenure
₹41,060,597
Compensation
Mr. Sridhar Subramaniam has been the Chief Executive Officer, Managing Director & Lead – Essential Health Portfolio of Pfizer Limited since March 18, 2016. He served as Business Unit Head of Pfizer Limited ...
CEO Compensation Analysis
Compensation vs Market: Sridhar's total compensation ($USD555.35K) is about average for companies of similar size in the Indian market ($USD775.42K).
Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD | 4.58yrs | ₹41.06m | no data | |
| CFO, Executive Director of Finance & Executive Director | 1.92yrs | ₹21.04m | no data | |
| Compliance Officer & Company Secretary | 13.08yrs | ₹5.22m | 0% ₹ 0 | |
| Executive Director & Executive Director of Legal | 0.67yr | ₹11.67m | no data | |
| Senior Director of Public Affairs | no data | no data | no data | |
| Director of Human Resources | no data | no data | no data |
7.7yrs
Average Tenure
52yo
Average Age
Experienced Management: 500680's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD | 4.58yrs | ₹41.06m | no data | |
| CFO, Executive Director of Finance & Executive Director | 1.92yrs | ₹21.04m | no data | |
| Executive Director & Executive Director of Legal | 0.67yr | ₹11.67m | no data | |
| Additional Independent Director | 1.58yrs | ₹1.76m | no data | |
| Non Executive Independent Chairman | no data | ₹1.99m | 0.0077% ₹ 18.4m | |
| Non Executive Independent Director | 5.67yrs | ₹1.79m | 0.0054% ₹ 12.8m | |
| Non-Executive Independent Director | 20.83yrs | ₹2.08m | no data | |
| Non Executive Independent Director | 8.42yrs | ₹2.02m | no data | |
| Director | 0.75yr | no data | no data |
3.8yrs
Average Tenure
60yo
Average Age
Experienced Board: 500680's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Pfizer Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Pfizer Limited
- Ticker: 500680
- Exchange: BSE
- Founded: 1950
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹237.351b
- Shares outstanding: 45.75m
- Website: https://www.pfizerindia.com
Number of Employees
Location
- Pfizer Limited
- The Capital
- 1802 / 1901, 18th Floor
- Mumbai
- Maharashtra
- 400051
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 500680 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Mar 1999 |
| PFIZER | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Mar 1999 |
Biography
Pfizer Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. It offers its various products in various therapeutic areas, including anti-allergic, anti ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/27 12:59 |
| End of Day Share Price | 2020/10/27 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.